225 related articles for article (PubMed ID: 30844555)
1. Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.
Hu Y; Nie H; Yu HH; Qin C; Wu LJ; Tang ZP; Tian DS
Autoimmun Rev; 2019 May; 18(5):542-548. PubMed ID: 30844555
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.
Tian X; Chen C; Ma L; Wei R; Li M; Wang X; Wu Y; Zhou Y; Cui Y
J Neuroimmunol; 2020 Oct; 347():577317. PubMed ID: 32731048
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study.
Zhao D; Zhao C; Lu J; Han Y; Sun T; Ren K; Ma C; Zhang C; Li H; Guo J
Mult Scler Relat Disord; 2023 Feb; 70():104518. PubMed ID: 36657326
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.
Alcalá C; Gascón F; Pérez-Miralles F; Gil-Perotín S; Navarré A; Boscá I; Coret F; Casanova B
J Neurol; 2018 Jul; 265(7):1690-1697. PubMed ID: 29785523
[TBL] [Abstract][Full Text] [Related]
6. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.
Castillo-Trivino T; Braithwaite D; Bacchetti P; Waubant E
PLoS One; 2013; 8(7):e66308. PubMed ID: 23843952
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for relapsing-remitting multiple sclerosis.
He D; Zhou H; Han W; Zhang S
Cochrane Database Syst Rev; 2011 Dec; (12):CD009130. PubMed ID: 22161445
[TBL] [Abstract][Full Text] [Related]
9. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Hauser SL; Waubant E; Arnold DL; Vollmer T; Antel J; Fox RJ; Bar-Or A; Panzara M; Sarkar N; Agarwal S; Langer-Gould A; Smith CH;
N Engl J Med; 2008 Feb; 358(7):676-88. PubMed ID: 18272891
[TBL] [Abstract][Full Text] [Related]
10. Effect of Rituximab on Expanded Disability Status Scale and Relapse Rate in Multiple Sclerosis Patients.
Mazdeh M; Khamseh M; Taheri M; Ghafouri-Fard S
J Mol Neurosci; 2020 Aug; 70(8):1165-1168. PubMed ID: 32144724
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in multiple sclerosis at general hospital level.
Hellgren J; Risedal A; Källén K
Acta Neurol Scand; 2020 Jun; 141(6):491-499. PubMed ID: 31990978
[TBL] [Abstract][Full Text] [Related]
12. Use of rituximab in adults with relapsing-remitting multiple sclerosis: a systematic literature review.
Siddiqui MK; Singh B; Attri S; Veraart C; Harty G; Wong SL
Curr Med Res Opin; 2020 May; 36(5):809-826. PubMed ID: 32129684
[No Abstract] [Full Text] [Related]
13. Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis.
Shima A; Hamaguchi T; Tada Y; Yamada M
Intern Med; 2020 Jan; 59(1):121-124. PubMed ID: 31462595
[TBL] [Abstract][Full Text] [Related]
14. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.
Massacesi L; Tramacere I; Amoroso S; Battaglia MA; Benedetti MD; Filippini G; La Mantia L; Repice A; Solari A; Tedeschi G; Milanese C
PLoS One; 2014; 9(11):e113371. PubMed ID: 25402490
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
Gold R; Radue EW; Giovannoni G; Selmaj K; Havrdova E; Stefoski D; Sprenger T; Montalban X; Cohan S; Umans K; Greenberg SJ; Ozen G; Elkins J
BMC Neurol; 2016 Jul; 16():117. PubMed ID: 27461166
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study.
Yamout BI; El-Ayoubi NK; Nicolas J; El Kouzi Y; Khoury SJ; Zeineddine MM
J Immunol Res; 2018; 2018():9084759. PubMed ID: 30539030
[TBL] [Abstract][Full Text] [Related]
18. Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
Zecca C; Bovis F; Novi G; Capobianco M; Lanzillo R; Frau J; Repice AM; Hakiki B; Realmuto S; Bonavita S; Curti E; Brambilla L; Mataluni G; Cavalla P; Di Sapio A; Signoriello E; Barone S; Maniscalco GT; Maietta I; Maraffi I; Boffa G; Malucchi S; Nozzolillo A; Coghe G; Mechi C; Salemi G; Gallo A; Sacco R; Cellerino M; Malentacchi M; De Angelis M; Lorefice L; Magnani E; Prestipino E; Sperli F; Brescia Morra V; Fenu G; Barilaro A; Abbadessa G; Signori A; Granella F; Amato MP; Uccelli A; Gobbi C; Sormani MP
Mult Scler; 2020 Oct; 26(12):1519-1531. PubMed ID: 31573386
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis.
Boremalm M; Sundström P; Salzer J
J Neurol; 2021 Jun; 268(6):2161-2168. PubMed ID: 33475825
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
